Researchers at the Feinstein Institute launched a clinical trial looking to explore the efficacy of bioelectronic medicine specifically designed to manage pain associated with lupus.
The study is exploring the use of a proprietary device, designed based upon previous research at the Feinstein Institute, which emits electrical pulses through a patient’s ear for five minutes a day over four days.
“Lupus is a painful disease, notoriously hard to diagnose and difficult to treat – new treatment options are desperately needed. This trial will study an innovative approach to controlling symptoms of a disease that affects millions. We hope to have encouraging findings very soon,” study lead investigator Dr. Cynthia Aranow said in a prepared statement.
Bioelectronic therapy is designed to help the body treat disease and injury without the use of pharmaceuticals and their associated side effects, the Feinstein Institute said.
In the current study, researchers hope to treat patients by stimulating the inflammatory reflex, and hope that the treatment will inhibit the body’s production of the molecule responsible for lupus-related inflammation.
“I am tremendously encouraged by the fast-paced advancement in this evolving field that we are seeing in the lab and in clinical trials. By intercepting and manipulating the millions of electrical messages that the body sends itself, we hope to produce therapies that are safer, more efficient and more cost-effective, and help the body heal itself,” Feinstein Institute Center for Bioelectronic Medicine director Chad Bouton said in a press release.
In July, the Feinstein Institute said it won a $1 million gift from the Knapp Family Foundation to launch a 4-year research program to explore bioelectronic medicine to treat diabetes.
Join us Oct. 8-10 for the 7th annual DeviceTalks Boston, back in the city where it all began.
DeviceTalks offers three days of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.
Early Registration is now open.